Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Study:

A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy

Rationale:

New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably.

Purpose:

This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

Study Status: Recruiting

Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Ototoxicity
Unspecified Childhood Solid Tumor, Protocol Specific
Procedure: management of therapy complications N/A

Verified by Children`s Oncology Group May, 2012

Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00458887

Study Type: Interventional

Study Design: N/A

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Lillian Sung, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site